At what enterprise value was NOVESCIA acquired in 2015?

During the acquisition of NOVESCIA by CERBA HEALTHCARE in 2015, the transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR.

What was the EV/EBITDA of NOVESCIA when it was acquired by CERBA HEALTHCARE?

The estimated EV/EBITDA multiple for NOVESCIA is in the range of 10x - 18x.

When was NOVESCIA acquired by CERBA HEALTHCARE?

NOVESCIA was acquired by CERBA HEALTHCARE in 2015.

What was the revenue of NOVESCIA at the time of the deal?

The revenue of NOVESCIA at the time of the deal is estimated to be in the range of 100M - 200M EUR.

What was the EBITDA of NOVESCIA during the acquisition?

NOVESCIA's EBITDA is estimated to be in the range of 10M - 30M EUR.

How is the data for the NOVESCIA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NOVESCIA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/nos-exclus/cerba-sempare-de-novescia-pour-275-m-108647

← DATABASE

Home Database Healthcare & PharmaNOVESCIA

01/2015

NOVESCIA acquired by CERBA HEALTHCARE

FRANCE Health Providers / Healthcare Facilities / Labs (Biology) EV 300M - 700M EUR

Context

Cerba acquired 100% of Novescia. The seller was a complex consortium managed by Ekkio Capital, including financial investors Cobepa and Socadif, as well as biologist shareholders. This acquisition allowed Cerba to reach critical mass in the routine segment, complementing its leadership in specialty testing.

NOVESCIA, which reported an EBITDA margin of in 2014, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Created from scratch in 2007 by Ekkio Capital, Novescia grew to become a major network of medical analysis laboratories in France. Unlike specialized labs, Novescia focused on "routine biology" (direct patient access) and clinic servicing (having acquired the biology division of Generale de Sante). At the time of the sale, the group operated approximately 100 laboratories organized around three main technical plateaus (Wissous, Lyon, Toulouse).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2014

2013

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
07/2015	ANTIN INFRASTRUCTURE	AMEDES	GERMANY	Labs (Biology)
05/2015	CINVEN	LABCO	FRANCE	Labs (Biology)
10/2014	WATERLAND	MEDIAN KLINIKEN	GERMANY	Clinics / Hospitals
09/2014	EURAZEO	COLISÉE	FRANCE	Nursing Homes
06/2014	PAI PARTNERS	DOMUSVI	FRANCE	Nursing Homes
03/2014	EQT PARTNERS	I-MED RADIOLOGY NETWORK	AUSTRALIA	Radiology
07/2012	MANAGEMENT & PRIVATE INVESTORS	LVL MEDICAL GERMANY	GERMANY	Outpatient Care
06/2012	AIR LIQUIDE	ORKYN (EX LVL MEDICAL)	FRANCE	Outpatient Care
12/2010	SAGA GROUP	NESTOR HEALTHCARE GROUP	UNITED KINGDOM	Outpatient Care
06/2010	PAI PARTNERS	CERBA HEALTHCARE	FRANCE	Labs (Biology)

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 100M - 200M EUR

EBITDA range: 10M - 30M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NOVESCIA by CERBA HEALTHCARE are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: cerba healthcare